Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

The patients are part of Cabaletta’s RESET program across inflammatory muscle condition myositis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Last month, the biotech shared ...

Lupus/SLE; and 6. Rheumatoid Arthritis as my diagnosed ... The agency said that scientists have no full understanding of what causes the condition. People with the condition are said to have ...

Peripheral Vascular Disease (PVD) is a common complication for those with diabetes, significantly impacting blood flow and ...

US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...

Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Gazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...